Evidence map›Paper›PMID 41688589›Full record

ReviewInflammopharmacology2026

Drug-disease interactions in inflammation: mechanisms, clinical Impact, and future directions.

Polu Picheswara Rao, Manish Vyas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Polu Picheswara RaoDepartment of Intellectual property Rights, Research and Development cell, Lovely Professional University, Jalandhar - Delhi Grand Trunk Rd, Phagwara, Punjab, 144411, India. kapil01pharm@gmail.com.ORCID http://orcid.org/0000-0003-3280-919X
Manish VyasResearch and Development cell, Parul University, Vadodara, Gujarat, 391760, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation is a complex biological response that varies significantly depending on the underlying disease or stress state, profoundly influencing the efficacy and safety of anti-inflammatory drugs. This review explores the multifaceted concept of drug-disease interactions in inflammatory conditions, highlighting how pathophysiological changes in autoimmune, metabolic, gastrointestinal, and infectious diseases modify pharmacokinetics and pharmacodynamics, thereby altering therapeutic responses and adverse effect profiles. We analyse a wide range of clinical studies and experimental models to elucidate the underlying mechanisms driving these interactions. The review further emphasizes personalized medicine approaches, including biomarker-guided therapies and pharmacogenomic insights, that enable tailored treatment strategies to improve patient outcomes. Strategies to optimize therapy in diverse disease states, such as drug repurposing and modulation in response to stress or comorbidities, are thoroughly examined. Additionally, emerging technologies and advanced experimental models are discussed to address current gaps and inform future research directions in conditional pharmacology. By synthesizing basic scientific knowledge with clinical practice, this comprehensive analysis aims to provide clinicians and researchers with critical insights necessary to enhance the safety and efficacy of anti-inflammatory treatments across a spectrum of inflammatory disorders.

Indexed as

Anti-Inflammatory AgentsInflammationAnimalsDrug InteractionsHumansPharmacogeneticsPrecision MedicineAnti-Inflammatory AgentsConditional pharmacologyDrug-disease interactionsInflammation pharmacologyPersonalized medicinePharmacogenomicsTherapeutic optimization

Identifiers

PMID41688589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.